29 March 2016 - Patients will be denied cutting-edge medicines because drugs companies are overcharging the NHS, the head of the treatments watchdog has said.

As the NICE regains full control of cancer drug assessments, it warns that new medicines will continue to be rejected unless companies lower their prices.

For more details, go to: http://www.thetimes.co.uk/tto/health/news/article4723397.ece